Lakewood-Amedex Biotherapeutics (LABT) Proxy filing summary

Executive summary

• Annual Meeting scheduled for September 22, 2026, to be held virtually, with record date set as July 30, 2026.

• Key proposals include director elections, amendments to articles of incorporation, equity plan changes, and auditor ratification.

• Board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Election of four directors for one-year terms.

• Proposal to increase authorized common stock from 12,500,000 to 100,000,000 shares.

• Authorization for the Board to effect one or more reverse stock splits up to a 1:20 ratio, at its discretion, before September 22, 2027.

• Amendment to the 2020 Equity Incentive Plan to increase shares issuable to 400,000.

• Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board consists of four members, three of whom are independent under Nasdaq standards.

• Committees established: Finance, Audit, and Risk; Compensation; Corporate Governance and Nominating.

• All committees are composed of independent directors and were constituted upon Nasdaq listing in April 2026.

• Board and committees oversee risk, compensation, governance, and nominations.

• Code of Business Conduct and Ethics applies to all directors, officers, and employees.